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GABAB receptor (GABABR) autoantibodies have been detected in the serum of
immunotherapy-responsive patients with autoimmune encephalitis. This study aimed
to investigate the effect of immunoglobulin G (IgG) from a patient with GABABR anti-
bodies on primary neuronal cultures and acute slices of entorhinal cortex. Primary hip-
pocampal neuronal cultures were incubated with serum immunoglobulin from
patients with GABABR or AMPA receptor (AMPAR) antibodies for up to 72 h to inves-
tigate their effect on receptor surface expression. Whole-cell patch-clamp recordings
from layer III pyramidal cells of the medial entorhinal cortex were used to examine
the effect on neuronal activity. GABABR surface expression was unaltered by incuba-
tion with GABABR antibodies. By contrast, after 24 h application of AMPAR antibod-
ies, AMPARs were undetectable. However, acute application of GABABR IgG
decreased both the duration of network UP states and the spike rate of pyramidal cells
in the entorhinal cortex. GABABR antibodies do not appear to affect GABABRs by
internalization but rather reduce excitability on the medial temporal lobe networks.
This unusual mechanism of action may be exploited in rational drug development
strategies.
KEY WORDS: Autoantibodies, Autoimmune encephalitis, Epilepsy, GABABR,
Whole-cell recordings.
Autoantibodies (Abs) to neuronal surface proteins com-
prise an expanding group of immunoresponsive central ner-
vous system (CNS) diseases.1 The pathogenic effects of
these Abs in vitro are usually considered to be mediated by
Ab-induced internalization of the antigenic target.2
Abs directed against the GABAB receptor (GABABR)
were originally described in patients with limbic encephali-
tis (LE) who presented with early seizures.3 Follow-up stud-
ies have shown an expanded phenotype, which includes
ataxia, opsoclonus-myoclonus syndrome, status epilepticus,
and Lambert-Eaton myasthenic syndrome (LEMS), usually
in the context of encephalitis.4–6 Some GABABR-Ab-
positive patients have responded well to immunotherapies;
however, many have a poor prognosis. Therefore, effective
treatment of GABABR-mediated encephalitis remains an
unmet medical need.
Higher cognitive functions rely on persistent cortical
activity, and dysregulation in cortical networks may result
in neurological impairment. During sleep and quiet wake-
fulness, cortical networks display intrinsic oscillations
between active UP states and quiescent DOWN states. In
the medial entorhinal cortex (mEC), these UP/DOWN states
are maintained in vitro7 and are partly regulated by GABA
receptors.8 Application of the GABABR antagonist
CGP55845 resulted in increased UP state duration, suggest-
ing tonic GABABR activity contributes to the spontaneous
termination of UP states.
The aim of this study was to investigate the effects of
GABABR-Abs on the surface expression of GABABRs in
primary neuronal cultures and their impact on activity in
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acute entorhinal cortex (EC) slices using whole-cell patch-
clamp recordings.
Methods
Cell-based assays and internalization experiments
Patients were chosen for whom we had a sufficient quan-
tity of serum with high levels of GABABR or AMPA recep-
tor (AMPAR) Abs. The research was approved by the
Oxfordshire Research Ethics Committee A (07 Q160X/28
and 07 Q1604/28). Immunoglobulin G (IgG) was purified
from a GABABR- and an AMPAR-Ab-positive patient as
previously described9 and shown to bind to GABABRs or
AMPARs in cell-based assays (CBAs). Briefly, human
embryonic kidney (HEK) cells were transiently transfected
with plasmids encoding either GABABR-1 and GABABR-2
or the AMPAR-1 and AMPAR-2 subunits. To assess effects
of antibodies on GABABR and AMPAR surface expression,
neuronal cultures were exposed to the patient IgG (100 lg/
mL; 1:100) for 1 or 24 h, followed by incubation with anti-
human IgG Alexa Fluor 488 secondary Ab, and visualized
by fluorescence microscopy.10
Electrophysiology and data analysis
Postnatal day 8–14 B57BL/6 mice were anesthetized
using isoflurane (4%–5%) and decapitated, according to
British Home Office regulations. Brains were removed and
placed in ice-cold artificial cerebrospinal fluid (aCSF;
126 mM NaCl, 3 mM KCl, 1.25 NaH2PO4, 1 mM MgSO4,
1 mM CaCl2, 24 mM NaHCO3, and 10 mM glucose, pH 7.2–
7.4), containing 3 mM kynurenic acid. Horizontal brain sec-
tions, 350 lm thick, containing the EC and hippocampus
were cut using a Leica VT1200S vibratome and incubated
in an interface chamber between humidified carbogen gas
(95% O2 and 5% CO2) and aCSF at room temperature for at
least 1 h prior to recording.
Electrophysiology and cell recordings
Slices were mounted on glass coverslips (coated with
0.1% poly-L-lysine) and placed in the recording chambers.
Slices were superfused with aCSF (bubbled with carbogen),
and the chamber maintained at a constant temperature
(31°–33°C). Whole-cell current-clamp recordings were
obtained from layer III mEC pyramidal neurons using
borosillicate glass pipettes (5–8 MΩ) filled with internal
solution containing 110 mM potassium gluconate, 40 mM
HEPES, 2 mM Mg-ATP, 0.3 mM NaGTP, and 4 mM NaCl
(adjusted to pH 7.2–7.3 with KOH). Signals were low-pass-
filtered at 2 kHz, acquired at 10 kHz using a Multiclamp
700B amplifier (Molecular Devices), and digitized using an
ITC-18 A/D board (Instrutech). Stimulation and recordings
were controlled using previously described custom-written
procedures8 in Igor Pro (Wavemetrics). UP states were
evoked every 30 s via a stimulation electrode placed in layer
III (LIII) approximately 200 lm away from the recorded
cell (stimulation strength: 100–200 lA, 100–200 ls). Cur-
rent was increased until reliable UP states were evoked.
Spike rate was defined as the spikes occurring during an
UP state event and reaching a threshold potential of
20 mV. UP states were recorded from the mEC and
compared in three conditions (at a flow rate of 5 mL/
min); baseline aCSF, IgG diluted in aCSF and applied to
brain sections at a concentration of 100 lg/mL, and a
final wash step. UP states were recorded for a minimum
of 10 min in each condition.
Statistical comparisons were made using repeated mea-
sures ANOVA, and Dunn’s multiple comparison post hoc
p < 0.05 was considered significant. All data are presented
as mean SEM.
Results
Patient selection and clinical data
IgG was purified from a 50-year-old male patient who
presented with confusion, unsteadiness, and proximal leg
weakness. Following respiratory failure, he was admitted
to the intensive care unit, and electroencephalogram
recordings revealed a diffuse encephalopathy; electromyo-
graphy was consistent with LEMS. Chest CT revealed a
small-cell lung carcinoma. The patient was treated with
plasma exchange and underwent chemotherapy for his
tumor, with good response. The patient had low serum
levels of voltage-gated calcium channel (VGCC)-Abs
(57 pM, normal <50 pM), but VGCC-Ab levels in the IgG,
purified from the plasma exchange eluate, were unde-
tectable. GABABR-Ab levels were high (end-point titra-
tion 1:1,000). IgG was also prepared from an AMPAR-Ab
patient (end-point titration 1:1,000) and from a healthy
individual (HC, 43-year-old male), with no prior neuro-
logical or autoimmune condition history, and whose
serum and IgG tested negative on all diagnostic CBAs.
IgG (100 lg/mL) purified from the GABABR-Ab-
positive patient showed strong immunoreactivity to the
extracellular domains of GABABR by CBA (Fig. 1A) and
strong binding to neuronal cultures after 1 h incubation,
which was retained at 24 h (Fig. 1D). In contrast, after incu-
bation with IgG (100 lg/mL) purified from a patient with
AMPAR-Abs, AMPAR expression was retained on the sur-
face of primary neuronal cultures at 1 h, but lost after 24 h
incubation (Fig. 1E).
Electrophysiology
Effect of IgG on UP state duration
UP states evoked by local synaptic stimulation in mEC
were monitored using whole-cell current-clamp recordings
from LIII pyramidal cells. No changes were noted when HC
IgG (Figs. 2A–B) was applied to the slices, in comparison
to baseline recordings or wash (baseline: 2.44  0.45 s,
HC IgG: 2.55  0.41 s, wash: 2.81  0.334 s, n = 5 slices
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from 4 mice, p = 0.23). Application of GABABR-Ab-posi-
tive IgG (Figs. 2D–E) revealed a 23% reduction in UP state
duration (baseline: 3.75  0.38 s vs. test IgG:
2.90  0.44 s, n = 6 slices, from 5 mice) in comparison to
baseline recordings (p = 0.0028). Washing of cells recov-
ered over 50% of the loss in UP state duration (wash:
3.35  0.37 s), suggesting that the effects are partially
reversible.
Effect of IgG on spike rate
Spike rate (mean spike count/mean UP state duration)
was not significantly altered following the application of
HC IgG on the slices (baseline: 1.81  1.57 vs. HC
IgG: 1.68  1.08; pooled data shown in Fig. 2C,
p = 0.9306). Following application of GABABR-Ab-
positive IgG to the slices, a 92% reduction in spike rate
was noted (baseline: 1.22  0.31 vs. test IgG:
0.10  0.16, p = 0.0185; Fig. 2E). Although no statisti-
cal significance existed between the baseline and the
wash recordings, a reduction was observed, perhaps
indicative of a partial washout.
These effects were abolished after IgG preadsorption
against HEK cells expressing GABABR (data not shown),
suggesting these are effects resulting from antigen-specific
modulation.
Discussion
The binding of Abs to extracellular epitopes in patients
with LE suggests these Abs are directly modulating epilep-
togenic neuronal networks. It has been demonstrated in vitro
that Abs to the NMDA receptor or AMPAR down-regulate
surface receptors.2,11 In contrast, the mechanism of action of
GABABR-Abs remains unknown.
In this study, IgG purified from a GABABR-Ab positive
patient did not internalize GABABRs. However, GABABR-
Abs modulated network activity in mEC slices. Acute appli-
cation of patient IgG caused a reduction in UP state duration
and spike rates in LIII pyramidal cells measured by whole-
cell patch-clamp recording. Synaptic inhibition plays an
important role in regulating the excitability of cortical net-
works, and the GABABR is important in regulating
Figure 1.
Expression studies of GABABR on transfected cells and neuronal cultures. Immunostaining of HEK cells expressing GABABR; 1:1 ratio,
GABABR1 and GABABR2 subunits (A) and HC serum (B) and compared to AMPAR-Ab-positive patient on HEK cells expressing 1:1 ratio
of AMPAR1 and AMPAR2: (C), dilution 1:100 in all cases, staining visualized with goat anti-human IgG, Alexa Fluor 488 (green), counter-
stained with DAPI (blue). Scale bar represents 50 lm. Cultured hippocampal neurons (div 14) were incubated with patient sera (1:100)
for 1 h, and staining was visualized with goat anti-human IgG Alexa Fluor 488 (green). Neurons were subsequently fixed, permeabilized,
and incubated with microtubule-associated protein 2 (MAP2; Alexa Fluor 568 (red)). Merged images are shown. GABABR-Ab IgG (green)
showed similar reactivity to neuronal cultures following 1 or 24 h incubation (D), suggesting surface expression is not affected. In con-
trast, AMPAR-Ab IgG staining was lost at 24 h (E). Scale bar represents 100 lm.
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Figure 2.
The effect of IgG on UP state duration and spike rate. (A–C) Effect of HC IgG (100 lg/mL) on UP states. Representative image showing
UP state duration and spike rate are unaffected following the application of HC IgG. Top panel: UP state recordings taken during baseline
recordings in aCSF. Middle panel: HC IgG (100 lg/mL). Bottom panel: following aCSF wash. LIII; Layer III, Stim; Stimulation (A). Following
application of HC IgG, UP state duration and spike rate were unaffected (pooled data from 4 slices) (B and C). (D–F) Effect of test IgG
(GABABR patient IgG) on UP states. Representative image showing both UP state duration and the spike rate were significantly reduced
following the application of patient IgG. Top panel: UP state recordings taken during baseline recordings in aCSF. Middle panel: test IgG
(100 lg/mL). Bottom panel: following aCSF wash. LIII; Layer III, Stim; Stimulation (D). UP state duration was significantly reduced follow-
ing the application of test IgG (**p = 0.0028, pooled data n = 6) (E). Similarly, a significant reduction was noted in spikes present during
UP state events following application of test IgG (*p = 0.0185, pooled data n = 5) (F).
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spontaneous GABA release in the EC,12 a region associated
with temporal lobe epilepsies. Interference of this mEC cir-
cuitry may disrupt the system, reducing hypoexcitability,
resulting in local epileptogenesis.
Our study provides the first evidence that GABABR-Abs
have a direct modulatory effect on the function of GABABR
at CNS synapses. Because the study was limited to one
patient by the large plasma volume required, future studies
should examine the effects from a range of GABABR-Ab
positive patients. The use of brain slices for whole-cell
recordings has numerous advantages but is an oversimplifi-
cation of the in vivo situation, and animal models should be
investigated to assess the pathogenic potential of these Abs.
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